

Att. Docket No. REG 203B-US
USSN 09/787,835
Amendment and Response to May 30, 2002.
Notification of Missing Requirements Under
35 USC 371 in the United States Designated/
Elected Office



portion. All sequences were sequence-verified using standard techniques. The coding sequence of IL-13R α 1.IL-4R α .Fc was then subcloned into the expression vector pCDNA3.1 (Stratagene) using standard molecular biology techniques.

REMARKS

This amendment is being made merely to conform the specification to the formal drawings that are being submitted herewith and to insert sequence identifiers. The drawing changes and amendment are needed in order to comply with the rules regarding drawings containing multiple views. Applicants submit herewith as Exhibit B: Marked -Up Versions of pages 6, 7, 8, 9, 10, 11, 12, 42, 49, 50, 51, 53, 55, 56, 62, 63, and 64.

Applicants contend that no new matter is introduced by these Amendments and, therefore, respectfully request entry of the Amendments.

Applicants submit herewith as Exhibit C: copy of the Transmittal of Sequence Listing (without exhibits) which is being submitted concurrently.

No fee is deemed necessary in connection with this submission. However, if any fee is deemed necessary, authorization is hereby given to charge the fee to Deposit Account No. 18-0650.

Linda O. Palladino
Reg. No. 45,636
Patent Agent for Applicants
Gail M. Kempler
Reg. No. 32,143
Joseph M. Sorrentino
Reg. No. 32,598
Laura J. Fischer
Reg. No. 50,420
Attorneys for Applicants
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591